R1	Has_index Arg1:T3 Arg2:T4	
R2	Has_temporal Arg1:T2 Arg2:T3	
*	OR T5 T6
R3	Subsumes Arg1:T8 Arg2:T9	
R4	Has_value Arg1:T8 Arg2:T10	
R5	AND Arg1:T7 Arg2:T8	
R6	Has_value Arg1:T12 Arg2:T13	
R7	AND Arg1:T11 Arg2:T12	
R8	Has_temporal Arg1:T14 Arg2:T15	
R9	Has_temporal Arg1:T16 Arg2:T17	
R10	Has_temporal Arg1:T18 Arg2:T19	
*	OR T11 T14 T16 T18
R11	Subsumes Arg1:T7 Arg2:T14	
R12	Has_temporal Arg1:T22 Arg2:T23	
T1	Non-query-able 0 180	Use of investigational drugs either within 5 half-lives of enrollment, or within 30 days, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer
T2	Procedure 183 196	Major surgery
T3	Temporal 204 301	last 3 months prior to baseline or planned major surgery or cardiac intervention during the study
T4	Reference_point 227 300	baseline or planned major surgery or cardiac intervention during the stud
T5	Condition 304 310	Cancer
T6	Condition 332 346	co-morbidities
T7	Condition 399 412	Comorbidities
T8	Measurement 450 469;475 481	natriuretic peptide levels
T9	Measurement 471 473	NP
T10	Value 441 449	elevated
T11	Condition 483 502	renal insufficiency
T12	Measurement 505 509	eGFR
T13	Value 510 529	< 25 ml/min/1.73 mÂ²
T14	Condition 597 612	cerebral trauma
T15	Temporal 577 595	less than 3 months
T16	Condition 644 668	cerebrovascular incident
T17	Temporal 624 642	less than 3 months
T18	Condition 689 715	acute exacerbation of COPD
T19	Temporal 727 740	last 3 months
T21	Non-query-able 743 834	Patients who are primarily managed and regularly followed-up by a cardiologist for their HF
T22	Observation 874 882	lifespan
T23	Temporal 944 962	less than 6 months
